Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004243142 | SCV003857882 | uncertain significance | not specified | 2022-12-19 | criteria provided, single submitter | clinical testing | The p.L688R variant (also known as c.2063T>G), located in coding exon 10 of the PALLD gene, results from a T to G substitution at nucleotide position 2063. The leucine at codon 688 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005036686 | SCV005657703 | uncertain significance | Pancreatic cancer, susceptibility to, 1 | 2024-05-15 | criteria provided, single submitter | clinical testing |